Slides
Page 1
Q3 2026 – Preliminary Results Presentation October 30, 2026
Page 2
This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person‘s officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Due to rounding, numbers presented throughout this report may not add up precisely to the totals indicated and percentages may not precisely reflect the absolute figures for the same reason. Disclaimer 10/30/2026 Gerresheimer AG – Prelim. Q3 2026 Results Presentation1
Page 3
Q3 2026 Preliminary Overview
Page 4
Executing transformation roadmap Q3 at EUR 103m Adj. EBITDA similar level as Q2; Expecting stronger Q4; Centor closed on Oct 1, exp. Primary Packaging Plastics closing in Q1 10/30/2026 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Q3 Adj. EBITDA at EUR 103m, margin at 17%; similar level as Q2; stronger Q4 expected Signed divestitures on 29 July – closing update: ✓ Centor: Closing completed October, 1st within 2 months only → PPP: Well on track to close already in Q1 27 Preparing refinancing in consent with banks; reducing debt and leverage to sustainable ~3x Transformation (gto) – Executing EUR 50-70m EBITDA improvement: Footprint Optimization (✓Chicago, next: Forest Grove) Operational Excellence; SG&A (targeting >20% HQ reduction YoY) Managing Portfolio: Grow – Medical Systems, Syringe Systems, Tubular Glas NA Fix – Tubular Glass Europe; right size SG&A Sell – Fixing first to prepare divestiture of Moulded Glass 3 Note: The reported figures in this presentation are preliminary and subject to completion of the final quarterly impairment analysis and IFRS5 “Divestiture” Accounting
Page 5
Q3 2025 Effects from Adjustments Resulted in ~unchanged revenues and EBITDA +3% 10/30/2026 561 560 Q3 2025 old Q3 2025 adjusted Δ0 Revenues* (EURm) Adj. EBITDA* (EURm) 103 106 Q3 2025 old Q3 2025 adjusted Δ3 Corrections consist of • Bill & Hold adjustments resulted in Revenues EUR -1m in Q3 25; EBITDA EUR ~0m • Other corrections impacted Q3 by EUR +1m in Revenues and by EUR +3m in EBITDA • BaFin investigation ongoing as expected – continuing full cooperation with authorities 18.4% 19.0% 4 1 3 -1 Revenues 0 Adj. EBITDA Bill and Hold Other 0 3 Gerresheimer AG – Prelim. Q3 2026 Results Presentation * including the business units currently in the sales process Q3 25 revenues unchanged, adj. EBITDA EUR +3m
Page 6
Stable EBITDA versus Q2 2026 10/30/2026 Q3 2025 prel. Q3 2026 560 605 +8% Revenues* (EURm) Adj. EBITDA* (EURm) Q3 with revenue increase of EUR 45m YoY; all segments contributing to revenue growth * including the business units currently in the sales process As Reported Revenues, Adjusted EBITDA and Cash Flow; FX as is Adjusted EBITDA decreased by EUR 3m YoY; A.o. lower EBITDA in Moulded Glass; Inventory rigor with EUR 20m reduction in 3Q26 vs. EUR 14m increase impacts profitability YoY 5 106 103 Q3 2025 prel. Q3 2026 21 -20 Q3 2025 prel. Q3 2026 17.1%19.0% Payables: Q3 26 with EUR 21m decrease, compared to EUR 18m increase in Q3 25 which was driven by increase of reverse factoring lines Receivables: Q3 26 with EUR 6m build-up aligned with higher sales vs. EUR 12m reduction in Q3 25 Inventories: EUR 20m reduction in Q3 26 (EUR 14m build-up in Q3 25) CapEx: Reduced Net CapEx YoY by EUR 8m from Q3 25 with EUR 64m to EUR 56m in Q3 26 FCF before M&A* (EURm) Q3 Revenues EUR +45m, Adj. EBITDA EUR -3m Year-on-Year Impacted by Inventory Rigor; Cash Flow EUR -20m as expected and aligned with CapEx spend Gerresheimer AG – Prelim. Q3 2026 Results Presentation Organically, adj. for Fx effects: 604m Organically, adj. for Fx effects: 17.6%
Page 7
Preliminary Q3 2026 Financial Performance
Page 8
Revenues and adj. EBITDA growth mainly driven by successful Peachtree ramp-up in Medical Devices Containment and Delivery Systems – Peachtree Ramp-Up Remains Growth Driver 10/30/2026 In EURm Revenues ▪ Revenues up EUR 27m YoY ▪ Continued ramp-up of the Peachtree site in the US driving growth ▪ Strong contribution from revenue growth in Primary Packaging Plastics (PPP) in Q3, pricing actions taking effect Revenues* Adj. EBITDA * * including the business units currently in the sales process and before consolidation 286 313 Q3 2025 prel. Q3 2026 +9% 64 77 Q3 2025 prel. Q3 2026 Adj. EBITDA ▪ EBITDA increased by EUR 13m YoY ▪ Solid revenue to EBITDA fall through from Medical Systems and Advanced Technology resource reductions in 2025 driving results YoY 22.3% 24.5% 7 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 9
Top- and bottom-line increase in Syringe Systems; Tubular Glass focus on restructuring at TG Europe Primary Injectable Solutions – Strong Quarter in Syringe Systems 10/30/2026 In EURm Revenues ▪ Revenues increase EUR 9m YoY and EUR 12m QoQ ▪ Increase mainly driven by Syringe Systems ▪ Tubular Glass stabilizing in terms of revenues (on YoY and QoQ basis) Revenues* Adj. EBITDA * * before consolidation Q3 2025 prel. Q3 2026 114 123 +8% 19 15 Q3 2025 prel. Q3 2026 Adj. EBITDA ▪ EBITDA declined by EUR 4m YoY , up EUR 5m QoQ ▪ Syringe Systems with significant improvement YoY and QoQ ▪ EBITDA in Tubular Glass remains weak YoY but stabilizes on QoQ basis; Focus remains on footprint optimization, operational excellence, SG&A savings and product portfolio optimization to improve profitability 16.8% 12.5% 8 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 10
Moulded Glass – Sales ~Flat YoY , EBITDA at 10% incl. strong inventory rigor 10/30/2026 Revenues ▪ Revenues ~flat; slightly up EUR 4m YoY and QoQ ▪ Flat pharma revenues, Europe offsetting YoY decline in Chicago Heights ▪ Food & Beverages similar level YoY ▪ Cosmetics slightly up YoY Revenues* Adj. EBITDA * * before consolidation 165 169 Q3 2025 prel. Q3 2026 +2% 29 17 Q3 2025 prel. Q3 2026 Adj. EBITDA ▪ EBITDA declined by EUR 12m YoY and EUR 10m QoQ, driven by strong inventory rigor / cash focus ▪ Chicago Heights plant closed in September17.4% 10.2% 9 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Chicago Heights plant closed in September In EURm
Page 11
* including the business units currently in the sales process Main Cash Flow Drivers: Funding transformation (Adj’ts), Interest and Tax as Expected, Continuing to Manage Capex Rigorously 10/30/2026 103 36 -20 9 5 20 32 Prel. Adj. EBITDA Δ NWC Net taxes paid Net interest paid Other Operating Cash Flow 56 Net Capex Prel. FCF before M&A EUR 20m inventory reduction Payables EUR -21m QoQ Revenue growth led to EUR -6m increase in Receivables Note: Q3 25 at EUR 64m By Type in Q3 26: -EUR ~27m base -EUR ~30m growth By Segment in Q3 26: -EUR ~23m CDS -EUR ~16m PIS -EUR ~17m MG 10 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Other CF mainly related to Adjustments (a.o. financing, gto, divestitures etc) and various effects including Fx
Page 12
1 Drawn portion of the RCF 2 Includes: local credit facilities/overdraft facilities/factoring liabilities exceeding EUR 93m 3 Excluding lease liabilities up to EUR 93m 4 As per Q3 2026 but reflecting subsequent changes in Bridge and Term Loan Financing Solid liquidity in Q3 2026; leverage covenant suspended up and including Q3; well positioned for a refinancing at ~3x leverage aligned with Centor & PPP closing Financing as of Prel. Q3 2026 – Solid Liquidity and Divestitures Reduce Debt 10/30/2026 Net Financial Debt as of Preliminary Q3 2026 In EURm Prel. Q3 2026 Q2 2026 Q3 2025 Revolving credit facilities1 Bridge loan / term loans Promissory loans Local borrowings2 Cash + cash equivalents Net Financial Debt3 Liquidity Maturity Profile in EURm4 11 633 725 870 30 -166 2,091 208 641 725 870 37 -215 2,058 249 75 780 1,208 16 -146 1,933 746 75 100 100 675 192166 525 347 257 42 Liquidity Q4 26 Q4 27 2028 2029 2030 2031 208 75 882 100 1,022 192 Cash Revolver Head Room Promissory Loans Bridge Loan Term Loan Revolver Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 13
Financial Reporting and Conferences End of November 2026 Publication Half-year Financial Report 2026 December 2026 Publication Quarterly Statement Q3 2026 March 2027 Publication Annual Report FY 2026 April 2027 Publication Quarterly Statement Q1 2027 August 2027 Publication Half-year Financial Report 2027 Upcoming Events 10/30/2026 Financial Calendar Investor Conferences 2026/27 Back-to-School Healthcare Series by Jefferies November 6 (Virtual) Global Healthcare Conference by Jefferies November 17, London Berenberg European Conference 2026 December 1 2026, London ODDO BHF Forum 2027 January 2027, Lyon German Investment Seminar by CoBa & ODDO BHF January 2027, New York 12 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 14
Executing Roadmap to profitable High Value Primary Packaging and Drug Delivery Solutions Provider Closing Remarks and Next Steps 10/30/2026 • Deliver strong Q4 to successfully finish 2026 • Closed Centor on 01 Oct; PPP transaction currently expected to close already in Q1 2027 • Targeting leverage at sustainable level of ~ 3x; well positioned for fulsome refinancing • Execute transformation measures targeting EUR 50 million to EUR 70 million of annualized EBITDA improvement by 2028 • New Moulded Glass leadership team to improve performance through rigorous restructuring; Product portfolio optimization in Primary Injectable Solutions to strengthen market position and support sustainable growth … Thank you for your continued support! 13 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 15
Appendix
Page 16
10/30/2026 Q2 2026 prel. Q3 2026 579 605 Revenues* (EURm) Adj. EBITDA* (EURm) All segments contributed to solid revenue increase in Q3 of EUR 26m vs. Q2 * including the business units currently in the sales process As Reported Revenues, Adjusted EBITDA and Cash Flow; FX as is Adjusted EBITDA increased moderately by +EUR 1m QoQ 15 102 103 Q2 2026 prel. Q3 2026 -92 -20 Q2 2026 prel. Q3 2026 17.1%17.6% Improvement in FCF EUR ~ +70m QoQ Main driver EUR +80m swing in NWC due to reduced inventories and higher payables. FCF before M&A* (EURm) Revenues Improved by EUR +26m; EBITDA stable and Cash Flow better by EUR +72m Gerresheimer AG – Prelim. Q3 2026 Results Presentation All segments contributing positively quarter on quarter
Page 17
2025 Effects from Restatements Resulted in Revenues +1% and EBITDA +5% 10/30/2026 Q3 2025 YTD old Q3 2025 YTD adjusted 1,681 1,705 Δ23 Revenues* Adj. EBITDA* -17 314 331 Q3 2025 YTD old Q3 2025 YTD adjusted Δ17 Corrections consist of • Bill & Hold adjustments resulted in Revenues EUR +25m and EBITDA EUR +8m in Q3 25 YTD • Other corrections impacted Q3 25 YTD by EUR -1m in Revenues and by EUR +9m in EBITDA • BaFin investigation ongoing as expected – continuing full cooperation with authorities 18.7% 19.4% 16 25 9 -1 8 Revenues Adj. EBITDA Bill and Hold Other 23 17 Gerresheimer AG – Prelim. Q3 2026 Results Presentation * including the business units currently in the sales process Q3 25 YTD impact of corrections referring revenues and adjusted EBITDA (EURm)
Page 18
10/30/2026 Q3 2025 YTD prel. Q3 2026 YTD 1,705 1,707 0% Revenues* (EURm) Adj. EBITDA* (EURm) Prel. Q3 26 YTD with ~ flat revenue (+EUR 2m); Growth in Containment & Delivery Systems offset by revenue decline in Injectable Solutions and Moulded Glass Adjusted EBITDA decreased by EUR -59m; cash focus with inventory rigor including temporary production halts impacted earnings 17 331 272 Q3 2025 YTD prel. Q3 2026 YTD -119 -141 Q3 2025 YTD prel. Q3 2026 YTD 15.9%19.4% Prel. Q3 26 YTD with EUR -133m decrease in payables vs. 40m in Q3 25 YTD; a -EUR 93m swing Q3 25 YTD with EUR 60m inventory build-up vs. Prel. Q3 26 YTD with EUR 1m reduction; a +EUR 61m YoY swing Q3 25 YTD with EUR 237m Net CapEx vs. prel. Q3 YTD 26 much reduced EUR 149m; a +EUR 89m YoY swing FCF before M&A* (EURm) EBITDA mainly driven by ~EUR 60m less Inventory Build and lower performance in TG Europe and Moulded Glass; FCF Impacted by ~EUR 80m less Reverse Factoring vs. Managing CapEx Gerresheimer AG – Prelim. Q3 2026 Results Presentation Organically, adj. for Fx effects: 1,709m Organically, adj. for Fx effects: EUR 281m /16.4% * including the business units currently in the sales process As reported revenues, adjusted EBITDA and cash flow; FX as is
Page 19
Containment and Delivery Systems – Peachtree Ramp Up Coming Through 10/30/2026 Revenues ▪ Increase driven by Medical Systems (MDS) with ramp-up of Peachtree Site in the US delivering results and strong revenue performance out of Eastern European plants ▪ Advanced Technology / MDS: Closer collaboration around own device strategy ▪ Primary Plastic Packaging (PPP) & Centor with stable revenue Q3 25 YTD Revenues* Adj. EBITDA * * including the business units currently in the sales process and before consolidation Q3 2025 YTD prel. Q3 2026 YTD 876 917 +5% 194 211 Q3 2025 YTD prel. Q3 2026 YTD Adj. EBITDA ▪ Solid revenue to EBITDA fall through from MDS and Advanced Technology resource reductions in 2025 driving results YoY ▪ Softer earnings in PPP & Centor from cash / inventory management and timing effects from cost increases 22.2% 23.0% 18 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Revenues and Adj. EBITDA growth mainly driven by successful Peachtree Ramp Up in Medical Devices In EURm
Page 20
Primary Injectable Solutions – Focusing on TG Europe Restructuring 10/30/2026 Revenues ▪ Revenue in Syringe Systems YoY down in Q3 YTD; increase in Q3 contributes to expected stronger H2 ▪ Revenue decline in Tubular Glass Europe & America Revenues* Adj. EBITDA * * before consolidation Q3 2025 YTD prel. Q3 2026 YTD 360 335 -7% 69 32 Q3 2025 YTD prel. Q3 2026 YTD Adj. EBITDA ▪ EBITDA decline driven by Tubular Glass ▪ Change in TG leadership and initiation of restructuring process with focus on footprint optimization, operational excellence and SG&A savings19.3% 9.5% 19 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Revenue decline ~2/3 driven by Tubular Glass and ~1/3 by Syringes Systems In EURm
Page 21
Chicago Heights plant closed Moulded Glass – Lower Revenue Combined with Inventory Reduction Led to Low Asset Utilization Impacting EBITDA 10/30/2026 In EURm Revenues ▪ Lower revenues in parenteral type 1 (Chicago Heights furnace repair) and type 3 pharma containers (Europe) were key drivers ▪ Chicago Heights plant closed End of September; qualifying/transferring Type 1 US Glass customers at/to European and Asian plants Revenues* Adj. EBITDA * * before consolidation Q3 2025 YTD prel. Q3 2026 YTD 492 479 -3% 91 52 Q3 2025 YTD prel. Q3 2026 YTD Adj. EBITDA ▪ Inventory reduction to address cash needs and the lower revenue together causing an underutilization of assets with high fall through to adj. EBITDA ▪ Cash focus and inventory rigor included extended temporary production halts 18.6% 10.9% 20 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 22
¹ Including leasing liabilities * Including the business units currently in the sales process FCF in Q3 26 YTD impacted by reduction of reverse factoring > EUR 80m (AP); managed Capex to less than 2/3 of last year 10/30/2026 272 8 -141 114 72 62 Prel. Adj. EBITDA Δ NWC 16 Net taxes paid Net interest paid Other Operating Cash Flow 149 Net Capex Prel. FCF before M&A Inventory of EUR +1m vs. EUR - 60m last year; YoY EUR +61m swing Payables EUR -133m includes EUR -84m less reverse factoring Receivables reduced EUR +20m Note: Q3 YTD 25 at EUR 237m = 1.6x By Type in Q3 YTD 26: -EUR ~61m base -EUR ~88m growth By Segment in Q3 YTD 26: -EUR ~55m CDS -EUR ~53m PIS -EUR ~53m MG 21 Gerresheimer AG – Prelim. Q3 2026 Results Presentation
Page 24
Moulded Glass*Primary Injectable Solutions Containment & Delivery Systems * Moulded Glass serves the three markets of pharmaceuticals, cosmetics, and food & beverages Next: Closing PPP Divestiture New Segmentation 2026 – Divestitures Accelerating Progress Towards High Value Primary Packaging and Drug Delivery Solutions 23 Syringe Systems Tubular Glass Primary Packaging Plastics Centor Medical Device Systems Advanced Technologies PPP (WIP) Centor (sold) Medical Device Systems Advanced Technologies Improving operations through restructuring; Progressing on carve out Divestiture Gerresheimer AG – Prelim. Q3 2026 Results Presentation10/30/2026
Page 25
FY 2026 Guidance (organic; before M&A) Guidance Gerresheimer Group – Unchanged* 10/30/202624 Gerresheimer AG – Prelim. Q3 2026 Results Presentation Adjusted EBITDA FY 2026 ~17-18% Margin Lower Half of EUR 2.3- 2.4bn EUR -50m to -100m Free CashflowRevenues * Including the business units currently in the sales process • Revenues for the full year with moderate to flattish growth over 2025 Level – confirming lower half of guidance range • EBITDA margin expected to improve during H2 26 mainly due to first efficiency (gto) measures coming through • Expecting negative Cash Flow of EUR -50 to -100m largely driven by less reverse factoring YoY